Simona Dinicola

Simona Dinicola

Auto-generated profile, based on publicly available information

Simona Dinicola

The Experts Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS), Rome, Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2018 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
SPSara Proietti
Sara Proietti
Angela CatizoneAngela Catizone
Angela Catizone
MMMaria Grazia Masiello
Maria Grazia Masiello
SDSimona Dinicola
Simona Dinicola
GFGianmarco Fabrizi
Gianmarco Fabrizi
Mariano BizzarriMariano Bizzarri
Mariano Bizzarri

1 January 2025 in Journal of Pregnancy
Verified
Journal Article
Open access
AOAli Cenk Ozay
Ali Cenk Ozay
ÖÖÖzlen Emekçi Özay
Özlen Emekçi Özay
OEOğuz Han EDEBAL
Oğuz Han EDEBAL
YÖYusuf Özay
Yusuf Özay
MOMario Montanino Oliva
Mario Montanino Oliva
Vittorio UnferVittorio Unfer
Vittorio Unfer
Objectives: Asprosin is a newly discovered adipokine associated with insulin resistance and diabetes mellitus. Currently, its role during gestation is under investigation, as asprosin seems to increase during pregnancy, contributing to the onset of complications, like gestational diabetes. Considering the beneficial effects of myo‐inositol to support the physiological pregnancy, recovering and preventing adverse maternal and fetal outcomes, we aimed to evaluate the effects of its supplementation on serum asprosin levels in pregnant women. Design: We enrolled 40 patients at the early stages of pregnancy and randomly distributed them to a study group, which received 2‐g myo‐inositol and 200‐ μ g folic acid twice a day, or to a control group, which received the sole folic acid. Results: After 20–22 weeks of treatment, we recorded a decrease of serum asprosin values as well as of HOMA‐IR index in the group supplemented with myo‐inositol, while the group that took only folic acid showed an increase in asprosin levels and no worsening of insulin resistance indices (HOMA‐IR index). Limitations: The small number of patients could be a limitation of the study. Conclusions: Asprosin may be modulated by myo‐inositol. This opens the possibility of considering this adipokine as a useful marker of insulin resistance to assess in pregnant women and to efficaciously target in clinical practice. Trial Registration: ClinicalTrials.gov identifier: NCT05943158.
1

1 March 2015 in Diabetes & Metabolism
Verified
Journal Article
Closed access
BFB. Fiquet
B. Fiquet
MDMartine Duclos
Martine Duclos
NPN. Postel-Vinay
N. Postel-Vinay
SDS. Dinicola
S. Dinicola
SQS. Quéré
S. Quéré
SDS. Dejager
S. Dejager